Tuesday, 15 Oct 2019

You are here

Vitamin D Supplements Fail to Prevent Type 2 Diabetes - DUH!

A NEJM report shows that the use of vitamin D3 supplementation (4000 IU per day) in those without diabetes or vitamin D deficiency failed to significantly lower risk of type 2 diabetes (compared to placebo).

The rational for this report included observational data showing an association between a low blood 25-hydroxyvitamin D level and the risk of type 2 diabetes.

They included adults who met at least two of three glycemic criteria for prediabetes (fasting plasma glucose level, 100 to 125 mg per deciliter; plasma glucose level 2 hours after a 75-g oral glucose load, 140 to 199 mg per deciliter; and glycated hemoglobin level, 5.7 to 6.4%). The primary outcome was the time to develop new-onset diabetes, with a target number of diabetes events of 508.

A total of 2423 participants were randomized to either vitamin D or placebo. By month 24, the mean serum 25-hydroxyvitamin D level in the vitamin D group was 54.3 ng per milliliter (up from 27.7 ng/ml at baseline), as compared with 28.8 ng per milliliter in the placebo group (baseline = 28.2 ng/ml).

The primary outcome of developing diabetes occurred

  • Vitamin D group: 293 events (9.39 per 100 person-years)
  • Placeboe group: 323 events (10.66  per 100 person-years)
  • Hazard ratio = 0.88 (95% confidence interval, 0.75 to 1.04; P=0.12)
  • No differences in the incidence of adverse events

(Editors note: I am continually amazed at the number of associations between vitamin D levels and poor health; yet there are little or not studies showing that Vitamin D Supplementation cures, fixes or prevents anything.  Certainly Vitamin D is important for bone health and immune function - but that's about where it ends.  I suggest we continue to take vitamin D supplements (since most of are deficient) daily and stop believing that this supplment is the magic bullet for health)


The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

ACR Responds to CY2020 Medicare Physician Fee Schedule Proposed Rule

Rheumatology leaders commend CMS for proposing E/M code changes and urge agency to make additional changes to final rule.d

Parenteral Out-Performs Oral Weekly Methotrexate

A systematic review in PLOS suggests that parenteral MTX therapy is more successful than oral MTX in achieving optimal disease activity control. 

ACR Survey Shows Half of Patients Cannot Afford Treatments

Americans living with rheumatic disease face significant healthcare challenges, according to a national patient survey released this week by the American College of Rheumatology. More than 1,500 U.S. adults living with rheumatic disease responded to the survey, which asked a range of questions related to healthcare access, affordability and lifestyle. Key findings include that even though 90 percent of respondents reported having health insurance coverage, nearly 60 percent said they had difficulty affording their medications or treatments in the past year.

Medical Use of Cannabis in 2019

JAMA has published an overview of cannabis and its medical uses. Although nearly 10% of cannabis users in the United States report using it for medicinal purposes, there is insufficient evidence to support the use of medical cannabis for most conditions for which its use is advocated or advised. Nevertheless, there is increase in favoring the public availability of cannabis, largely for the management of more than 50 medical conditions.

Steroid Sparing Effects of Methotrexate and Mycophenolate in Uveitis

Patients with noninfectious uveitis (intermediate, posterior uveitis, or panuveitis) often require high dose corticosteroids and therefore may need steroid-sparing DMARD therapy. The FAST study investigated the corticosteroid-sparing effect of methotrexate or mycophenolate mofetil in adults with noninfectious uveitis.